Renaissance Technologies LLC Raises Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Renaissance Technologies LLC lifted its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 18.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,804,557 shares of the company's stock after purchasing an additional 280,327 shares during the period. Renaissance Technologies LLC owned about 1.23% of MiMedx Group worth $17,360,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of MDXG. IMG Wealth Management Inc. bought a new position in MiMedx Group in the 4th quarter worth $28,000. Van ECK Associates Corp bought a new position in shares of MiMedx Group in the fourth quarter worth about $40,000. SkyView Investment Advisors LLC grew its position in shares of MiMedx Group by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock worth $77,000 after purchasing an additional 3,000 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of MiMedx Group during the fourth quarter worth about $88,000. Finally, Savant Capital LLC bought a new stake in MiMedx Group during the 4th quarter valued at approximately $100,000. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Price Performance

Shares of NASDAQ MDXG traded up $0.03 during midday trading on Tuesday, reaching $6.80. 485,159 shares of the stock traded hands, compared to its average volume of 696,169. The company's 50 day moving average is $7.79 and its 200 day moving average is $8.00. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The stock has a market capitalization of $1.00 billion, a PE ratio of 12.36 and a beta of 1.74.

Remove Ads

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $92.91 million during the quarter, compared to analysts' expectations of $89.42 million. On average, equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MDXG. StockNews.com upgraded shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

Insider Activity at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 54,596 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 144,018 shares of company stock worth $1,130,312. Company insiders own 1.30% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.